Race and ethnicity sub-groups of alopecia areata patients have differing clinical characteristics: TARGET-DERM AA

Maria K Hordinsky MD¹; Claire Bristow PhD MPH, MSc²; Sven Richter MD²; Ahmed M Soliman PhD MS²; Keith D Knapp PhD³; Breda Munoz PhD³; Julie M Crawford MD³; Amy S Paller MD⁴; M. Shane Chapman MD, MBA⁵; Lara Wine Lee MD⁶; Natasha A Mesinkovska MD, PhD⁷; Benjamin N Ungar MD⁸

¹University of Minnesota Medical School, Minnesota; ²AbbVie Inc. Illinois; ³Target RWE, North Carolina; ⁴Northwestern University - The Feinberg School of Medicine, Illinois; ⁵Dartmouth-Hitchcock Medical Center – Geisel School of Medicine at Dartmouth, New Hampshire; ⁶Medical University of South Carolina, South Carolina; ⁷University of California School of Medicine, Illinois; ⁸Icahn School of Medicine at Mount Sinai, New York

Introduction

- Alopecia areata (AA) is a chronic autoimmune disease that disproportionately impacts select subgroups.¹
- Specifically, patients with skin of color seem have a higher prevalence of AA.²

Objective

• To assess clinical characteristics of AA patients by race and ethnicity subgroup.

 Table 1. Demographic Characteristics at enrollment by race/ethnicity

	NH White (N=139)	NH Black (N=23)	NH Asian (N=17)	Hispanic (N=76)	NH White or NH Black or NH Asian or Hispanic (N=255)	p-value compares NH White, NH Black, NH Asian and Hispanic	Other/Not Reported (N=12)	All participants (N=267)
Adult Age						0.0019		
Mean (SD)	46.3 (16.2)	34.0 (11.9)	37.0 (10.9)	32.7 (12.6)	42.5 (16.0)		38.9 (17.8)	42.3 (16.0)
Median (n)	48.0 (93)	38.0 (11)	34.0 (11)	29.5 (20)	43.0 (135)		39.0 (7)	42.5 (142)
Min - Max	18.0 - 77.0	19.0 - 54.0	23.0 - 54.0	19.0 - 52.0	18.0 - 77.0		19.0 - 71.0	18.0 - 77.0
Sex, n (%)						0.8361		
Female	87 (62.6%)	13 (56.5%)	10 (58.8%)	45 (59.2%)	155 (60.8%)		9 (75.0%)	164 (61.4%)
Insurance, n (%)						<.0001		
n	139	23	17	76	255		12	267
Commercial/Private	120 (86.3%)	18 (78.3%)	15 (88.2%)	38 (50.0%)	191 (74.9%)		5 (41.7%)	196 (73.4%)
Medicaid	8 (5.8%)	5 (21.7%)	2 (11.8%)	37 (48.7%)	52 (20.4%)		6 (50.0%)	58 (21.7%)
Medicare	9 (6.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	9 (3.5%)		1 (8.3%)	10 (3.7%)
Uninsured	2 (1.4%)	0 (0.0%)	0 (0.0%)	1 (1.3%)	3 (1.2%)		0 (0.0%)	3 (1.1%)




Characteristic	NH White (N=139)	NH Black (N=17)	NH Asian (N=8)	Hispanic (N=43)	NH White or NH Black	p-value compares	Other/Not Reported	All participants
					or NH Asian or Hispanic	NH White, NH Black,	(N=43)	(N=267)
					(N=207)	NH Asian and		
						Hispanic		
PGIS-AA, n (%)	136	17	8	43	204	0.4950	60	264
n	10 (7.4%)	1 (5.9%)	0 (0.0%)	4 (9.3%)	15 (7.4%)		4 (6.7%)	19 (7.2%)
1. None	31 (22.8%)	4 (23.5%)	1 (12.5%)	14 (32.6%)	50 (24.5%)		22 (36.7%)	
2. Mild	41 (30.1%)	5 (29.4%)	3 (37.5%)	14 (32.6%)	63 (30.9%)		13 (21.7%)	
3. Moderate	27 (19.9%)	2 (11.8%)	1 (12.5%)	8 (18.6%)	38 (18.6%)		14 (23.3%)	
4. Severe 5. Very Severe	27 (19.9%)	5 (29.4%)	3 (37.5%)	3 (7.0%)	38 (18.6%)		7 (11.7%)	45 (17.0%)
PGIS-AA, n (%)	136	17	8	43	204	0.4581	60	264
None, Mild or Moderate	82 (60.3%)	10 (58.8%)	4 (50.0%)	32 (74.4%)	128 (62.7%)		39 (65.0%)	
Severe or Very severe	54 (39.7%)	7 (41.2%)	4 (50.0%)	11 (25.6%)	76 (37.3%)		21 (35.0%)	
AAPO - Hair loss	4.1 (2.9)	4.6 (4.1)	1.8 (0.5)	2.6 (2.1)	3.8 (2.9)	0.0513	3.0 (2.6)	3.7 (2.9)
Mean (SD)	4.0 (87)	2.5 (10)	2.0 (4)	2.0 (20)	3.0 (121)		2.5 (30)	3.0 (151)
Median (n)	0.0 - 12.0	1.0 - 11.0	1.0 - 2.0	0.0 - 8.0	0.0 - 12.0		0.0 - 12.0	0.0 - 12.0
AAPO - Emotional Symptoms	8.3 (4.8)	7.9 (5.7)	9.8 (3.1)	8.1 (4.8)	8.3 (4.8)	0.9192	8.7 (4.5)	8.4 (4.7)
Mean (SD)	8.0 (120)	4.0 (11)	9.0 (6)	8.0 (24)	8.0 (161)		8.0 (35)	8.0 (196)
Median (n)	0.0 - 16.0	2.0 - 16.0	6.0 - 14.0	0.0 - 14.0	0.0 - 16.0		0.0 - 16.0	0.0 - 16.0
AAPO - Activity Limitations	1.7 (2.5)	2.0 (2.9)	1.0 (1.5)	1.9 (2.6)	1.7 (2.5)	0.9906	1.7 (2.5)	1.7 (2.5)
Mean (SD)	0.0 (118)	0.5 (10)	0.5 (6)	0.0 (23)	0.0 (157)		0.5 (34)	0.0 (191)
Median (n)	0.0 - 9.0	0.0 - 9.0	0.0 - 4.0	0.0 - 6.0	0.0 - 9.0		0.0 - 9.0	0.0 - 9.0
PROMIS Anxiety	52.5 (9.1)	48.7 (11.7)	50.7 (13.7)	50.0 (9.4)	51.7 (9.5)	0.3761	49.9 (9.0)	51.3 (9.5)
Mean (SD)	52.5 (127)	50.5 (14)	53.7 (7)	49.8 (33)	51.2 (181)		49.1 (48)	51.2 (229)
Median (n)	33.5 - 73.3	33.5 - 71.2	33.5 - 69.3	33.5 - 64.5	33.5 - 73.3		33.5 - 67.3	33.5 - 73.3
PROMIS Depression	49.4 (9.1)	48.2 (10.8)	49.9 (13.3)	46.2 (8.0)	48.8 (9.2)	0.4903	47.5 (8.5)	48.5 (9.1)
Mean (SD)	49.0 (127)	47.3 (14)	49.0 (7)	45.5 (31)	49.0 (179)		47.4 (48)	49.0 (227)
Median (n)	35.2 - 76.5	35.2 - 69.4	35.2 - 67.5	35.2 - 65.7	35.2 - 76.5		35.2 - 69.3	35.2 - 76.5



Methods

- United States and Canadian clinics enrolled participants in the TARGET-DERM AA registry (December 2021 - June 2024, data collection ongoing).
- Inclusion criteria:
 - Enrolled in TARGET-DERM AA
 - Completed a patient questionnaire at enrollment
 - Had at least one clinician reported outcome at enrollment
- The patient questionnaire invites responses regarding comorbidities and the Patient Global Impression of Severity-AA (PGIS-AA).
- Clinician-reported outcomes collected: the Clinician's Global Impression of AA (CGI-AA), Severity of

Figure 1. Distribution by
Race/EthnicityFigure 2. Proportion of patients in each
subgroup with the named outcomes



Results

- Eyelash involvement was highest in NH Black patients, followed by NH White, NH Asian, and Hispanic patients (39.1%, 34.7%, 35.3%, and 17.1%, respectively, Figure 2).
- Across race/ethnicity subgroups at enrollment, there were no significant differences in the use

Alopecia Tool (SALT), Measure for Eyebrow and Eyelash Hair Loss.

 Patients were summarized using descriptive statistics and compared using the Fisher-Exact, Chi-square, or Kruskal-Wallis tests as appropriate.

Results

- Of the 267 AA patients, 61.4% were female; 53.2% were adults. (Table 1)
- 52.1% identified as Non-Hispanic (NH) White, 28.5% identified as Hispanic, 8.6% NH Black and 6.4% as NH Asian. (Figure 1)
- Of all subgroups, the NH Asian patients had the highest proportion (47.1%) with severe disease (SALT>50) followed by (Figure 2):
 - 34.8% of NH Black patients

	NH White (N=139)	NH Black (N=23)	NH Asian (N=17)	Hispanic (N=76)	NH White or NH Black or NH Asian or Hispanic (N=255)	p-value compares NH White, NH Black, NH Asian and Hispanic	All participants (N=267)
Topical							
Corticosteroids, n (%)							
Fluocinolone	4 (2.9%)	3 (13.0%)	1 (5.9%)	3 (3.9%)	11 (4.3%)		12 (4.5%)
Betamethasone	6 (4.3%)	0 (0.0%)	2 (11.8%)	2 (2.6%)	10 (3.9%)		10 (3.7%)

32 (23.0%) 1 (4.3%) 6 (35.3%) 25 (32.9%) 64 (25.1%)

24 (17.3%) 4 (17.4%) 4 (23.5%) 13 (17.1%) 45 (17.6%) 0.5742

24 (17.3%) 3 (13.0%) 3 (17.6%) 4 (5.3%) 34 (13.3%) 0.3623

20 (14.4%) 1 (4.3%) 2 (11.8%) 2 (2.6%) 25 (9.8%) 0.1325

7 (5.0%) | 1 (4.3%) | 2 (11.8%) | 1 (1.3%) | 11 (4.3%) | 0.6617 | 11 (4.1%)

* The column entitled "Other/Not-reported" (N=12) is not shown.

Table 3. Clinician-reported outcomes at enrollment by race/ethnicity

subgroup

Clobetasol

Oral Minoxidil

Baricitinib

Tofacitinib

Topical Minoxidi

NH White	NH Black	NH Asian	Hispanic	NH White	p-value	Other/No	All	NH White
(N=139)	(N=23)	(N=17)	(N=76)	or NH	compares NH	t	participan	(N=139)
				Black	White,	Reported	ts	
				or NH	NH Black,	(N=12)	(N=267)	
				Asian or	NH Asian and			
				Hispanic	Hispanic			
				•	пізрапіс			
				(N=255)		0.0204		
SALT						0.0284		
Mean (SD)	41.3 (37.3)		41.5 (43.2)	26.7 (32.3)	37.0 (37.3)		22.6 (30.3)	36.3 (37.1)
Median (n)	28.0 (139)	19.3 (23)	10.0 (17)	11.9 (76)	21.0 (255)		8.3 (12)	19.8 (267)
Min - Max	1.0 - 100	1.8 - 100	1.2 - 100	1.2 - 100	1.0 - 100		1.2 - 100	1.0 - 100
CGI-AA						0.0610		
Mean (SD)	2.4 (1.1)	2.3 (1.3)	2.3 (1.3)	1.9 (1.0)	2.2 (1.1)		1.9 (1.0)	2.2 (1.1)
Median (n)	2.0 (139)	2.0 (23)	2.0 (17)	2.0 (76)	2.0 (255)		2.0 (12)	2.0 (267)
Min - Max	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0	1.0 - 4.0		1.0 - 4.0	1.0 - 4.0
Percent Hair loss						0.0120		
Mean (SD)	43.2 (35.9)	44.0 (42.3)	44.8 (41.9)	27.6 (31.6)	38.7 (36.3)		26.1 (28.7)	38.1 (36.0)
Median (n)	30.0 (138)	23.0 (23)	25.0 (17)	15.0 (76)	25.0 (254)		17.5 (12)	24.0 (266)
Min - Max	1.0 - 100	2.0 - 100	1.0 - 100	1.0 - 100	1.0 - 100		2.0 - 100	1.0 - 100
Eyebrow						0.0375		
Mean (SD)	1.0 (1.3)	0.6 (0.9)	1.1 (1.4)	0.5 (0.9)	0.8 (1.2)		0.9 (1.2)	0.8 (1.2)
Median (n)	0.0 (139)	0.0 (23)	0.0 (17)	0.0 (76)	0.0 (255)		0.0 (12)	0.0 (267)
Min - Max	0.0 - 3.0	0.0 - 3.0	0.0 - 3.0	0.0 - 3.0	0.0 - 3.0		0.0 - 3.0	0.0 - 3.0
Eyelash						0.0146		
Mean (SD)	0.9 (1.3)	0.8 (1.1)	0.9 (1.3)	0.4 (0.9)	0.7 (1.2)		0.3 (0.9)	0.7 (1.2)
Median (n)	0.0 (139)	0.0 (23)	0.0 (17)	0.0 (76)	0.0 (255)		0.0 (12)	0.0 (267)
Min - Max	0.0 - 3.0	0.0 - 3.0	0.0 - 3.0	0.0 - 3.0	0.0 - 3.0		0.0 - 3.0	0.0 - 3.0

of topical treatments or in the use of systemic Janus Kinase Inhibitors (Table 2).

Conclusion:

67 (25.1%)

46 (17.2%)

36 (13.5%)

26 (9.7%)

- In this large real-world cohort, we identified differences in clinician reported measures by race/ethnicity subgroup.
- NH-Asian patients represented the largest proportion of patients with patient and clinician-reported severe disease.
- Clinician-reported eyebrow hair loss was most prevalent in NH White patients, while eyelash hair loss was most prevalent in NH Black patients.
- Hispanic patients had the smallest proportion with severe SALT, eyebrow and eyelash involvement.
 Additional research is required to better characterize AA and health-related quality of life burden in non-White AA patients.

- 31.7% of NH White patients
- 19.7% of Hispanic AA patients
- Across the subgroups HS Asian patients also had the highest proportion (47.1%) of patient-reported severe/very severe disease (PGIS-AA) followed by (Figure 2):
 - 41.9% of NH White patients
 - 39.1% of NH Black patients
 - 27.6% of Hispanic AA patients
- Eyebrow involvement was highest in NH White patients (44.6%), followed by NH Asian (41.2%), NH Black (34.8%), and Hispanic AA patients (26.3%, Figure 2)

References

- 1. Lee H, Jung SJ, Patel AB, Thompson JM, Qureshi A, Cho E. Racial characteristics of alopecia areata in the United States. Journal of the American Academy of Dermatology 2020;83:1064-70.
- Moseley, I. H., et al. (2023). "Alopecia areata in underrepresented groups: preliminary analysis of the all of us research program." Archives of Dermatological Research 315(6): 1631-1637.

Acknowledgements and Disclosures: TARGET-DERM is a study sponsored by Target RWE. Target RWE is a health evidence solutions company headquartered in Durham, NC. The authors would like to thank all the investigators, participants, and research staff associated with TARGET-DERM. *TARGET-DERM Investigators are the participating investigators who provided and cared for study patients; they are authors and non-author contributors. For the complete list, please see ClinicalTrails.gov (NCT03661866). **MKH** has functioned as an advisory board member or investigator (funds paid to institution) for Arcutis Biotheraputics, Abbvie, Eli Lilly, Pfizer, RegenLab, SUN Pharmaceuticals, Cassiopea, and the National Alopecia Areata Foundation; **BNU** had research funds paid to institution from: Incyte, Pfizer, and Rapt. He consulted for: Arcutis Biotherapeutics, Bristol Myers Squib, Castle Biosciences, Fresenius Kabi, Galderma, Pfizer, Primus Pharmaceuticals, Sanofi, and UCB. **NAM** has rendered professional services to AbbVie, Arena Pharmaceuticals, Bristol Myers Squibb, Concert Pharmaceuticals, Eli Lilly, Calderma, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy, and UCB; and has served on AbbVie and Galderma Data Safety Monitoring Boards; **MSC** was an investigator for Biofronterra; **LWL** has rendered professional services to Castle Creek Biosciences, Eli Lilly, Pfizer, Regeneron Pharmaceuticals, Inc., Chiesi, AbbVie, Amryt Pharma, Krystal Biotech, Novartis, Kimberly Clark– consultant; AbbVie, Amgen, Amryt Pharma, Arcutis Biotherapeutics, Castle Creek Biosciences, Celgene, Eli Lilly, Galderma, Incyte, Mayne Pharmaceuticals, MoonLake Pharmacuetical, Novartis, Pfizer, Regeneron Pharmaceutical, Novartis, Pfizer, R